Comparison of uric acid elevation between aspirin-ticagrelor and aspirin-clopidogrel during dual antiplatelet therapy.

IF 0.9 4区医学 Q4 PHARMACOLOGY & PHARMACY International journal of clinical pharmacology and therapeutics Pub Date : 2024-09-18 DOI:10.5414/CP204606

Sojin Park, Sangah Chi, Jeong Hoon Yang, Myungsook Min, Ju-Young Shin

{"title":"Comparison of uric acid elevation between aspirin-ticagrelor and aspirin-clopidogrel during dual antiplatelet therapy.","authors":"Sojin Park, Sangah Chi, Jeong Hoon Yang, Myungsook Min, Ju-Young Shin","doi":"10.5414/CP204606","DOIUrl":null,"url":null,"abstract":"Objective: This study investigated whether serum uric acid levels are more elevated in the aspirin-ticagrelor group than in the aspirin-clopidogrel group. Materials and Materials and methods: We conducted a retrospective cohort study with patients between 2013 and 2020. Baseline and maximum serum uric acid levels within a 6-month follow-up period were analyzed to determine the increase in both groups.Results: A total of 41,877 patients were enrolled. A statistically significant elevation of serum uric acid levels was found in the aspirin-ticagrelor group compared to the aspirin-clopidogrel group (odds ratio (OR; 95% confidence interval (CI)) = 1.36 (1.15 - 1.60), p < 0.001). Kidney dysfunction and diuretic use were also identified as risk factors for uric acid elevation.Conclusion: Monitoring serum uric acid levels is recommended during aspirin-ticagrelor therapy, especially in patients with kidney dysfunction or those using diuretics.","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of clinical pharmacology and therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5414/CP204606","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study investigated whether serum uric acid levels are more elevated in the aspirin-ticagrelor group than in the aspirin-clopidogrel group. Materials and Materials and methods: We conducted a retrospective cohort study with patients between 2013 and 2020. Baseline and maximum serum uric acid levels within a 6-month follow-up period were analyzed to determine the increase in both groups.

Results: A total of 41,877 patients were enrolled. A statistically significant elevation of serum uric acid levels was found in the aspirin-ticagrelor group compared to the aspirin-clopidogrel group (odds ratio (OR; 95% confidence interval (CI)) = 1.36 (1.15 - 1.60), p < 0.001). Kidney dysfunction and diuretic use were also identified as risk factors for uric acid elevation.

Conclusion: Monitoring serum uric acid levels is recommended during aspirin-ticagrelor therapy, especially in patients with kidney dysfunction or those using diuretics.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

阿司匹林-替卡格雷与阿司匹林-氯吡格雷双重抗血小板治疗期间尿酸升高的比较。

研究目的本研究探讨了阿司匹林-替卡格雷组的血清尿酸水平是否比阿司匹林-氯吡格雷组更易升高。材料和方法：我们对 2013 年至 2020 年期间的患者进行了一项回顾性队列研究。对随访 6 个月内的基线和最高血清尿酸水平进行了分析，以确定两组尿酸水平的升高情况：共有 41877 名患者参与了研究。与阿司匹林-氯吡格雷组相比，阿司匹林-替卡格雷组的血清尿酸水平升高具有统计学意义（几率比（OR；95% 置信区间（CI））= 1.36 (1.15 - 1.60)，P < 0.001）。肾功能障碍和使用利尿剂也是尿酸升高的风险因素：建议在阿司匹林-替卡格雷治疗期间监测血清尿酸水平，尤其是肾功能不全或使用利尿剂的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International journal of clinical pharmacology and therapeutics 医学-药学

CiteScore

1.70

自引率

12.50%

发文量

116

审稿时长

4-8 weeks

期刊介绍： The International Journal of Clinical Pharmacology and Therapeutics appears monthly and publishes manuscripts containing original material with emphasis on the following topics: Clinical trials, Pharmacoepidemiology - Pharmacovigilance, Pharmacodynamics, Drug disposition and Pharmacokinetics, Quality assurance, Pharmacogenetics, Biotechnological drugs such as cytokines and recombinant antibiotics. Case reports on adverse reactions are also of interest.